Editas Medicine (EDIT) Morgan Stanley 22nd Annual Global Healthcare Conference summary

Strategic focus and pipeline updates

• Strategy centers on three pillars: advancing reniz-cel for sickle cell disease, building in vivo gene editing capabilities, and monetizing intellectual property through licensing.

• Reniz-cel has shown unprecedented efficacy, with treated patients experiencing no vaso-occlusive events and correction of anemia to normal hemoglobin levels.

• Enrollment for both adult and adolescent cohorts in the reniz-cel program has been completed ahead of schedule, reflecting strong interest.

• In vivo editing efforts focus on functional upregulation rather than knockdown, targeting diseases with poor or no standard of care and leveraging rapid biochemical readouts.

• Proof of concept for in vivo editing is expected by year-end, with details on editing efficiency and market potential to be shared, but specific targets withheld for competitive reasons.

Differentiation and technology platform

• The platform is distinguished by its focus on upregulation using clinically validated Cas12a, setting it apart from knockdown-centric approaches.

• Human genetics and large biobank datasets are used to de-risk target selection and identify opportunities for upregulation in diseases of haploinsufficiency.

• Delivery strategies prioritize lipid nanoparticles (LNPs) for liver and hematopoietic stem cell targeting, moving away from AAV to focus expertise.

• Manufacturing timelines for reniz-cel have been optimized, with turnaround times now primarily dependent on patient-specific factors.

Clinical and commercial outlook

• Upcoming year-end data will include expanded and longer-term follow-up from both the RUBY (sickle cell) and EdiTHAL (thalassemia) studies, aiming to match or exceed benchmarks set by competitors.

• Reniz-cel is differentiated by durable correction of anemia and absence of vaso-occlusive events, with strong manufacturing performance.

• Commercial strategy is to be a fast follower in the U.S., leveraging established market infrastructure and focusing on a highly targeted specialty sales force.

• Pricing is expected to align with current market standards ($2–3 million per treatment), with a focus on capital efficiency and patient access.

• Ex-U.S. launches will depend on partnerships, with initial focus on the U.S. market.